- AdventHealth Research Institute
What we eat has a big impact on the bacteria living in our gut, which in turn affects how our bodies use energy—something that plays a major role in the development and treatment of obesity. Most of what we know about this comes from animal studies or human observations, so there is still a lot to learn.
Our recent study, published in the American Journal of Clinical Nutrition, aimed to fill in some of these gaps. We looked at small molecules in the body—called metabolites—including those that are produced when food is digested by both our bodies and the microbes in our gut.
We studied healthy adults without obesity and fed them two different diets:
• A high-fiber diet (called the Microbiome Enhancer Diet or MBD), which was low in processed foods.
• A Western-style diet (WD), which was low in fiber and high in processed foods.
Both diets had the same number of calories and macronutrient percentages, and participants were carefully monitored to make sure they ate exactly what was provided.
Our study goals were:
1. To find chemical “fingerprints” of each diet that could be validated in future research.
2. To understand how diet and gut microbes work together to affect how much energy the body absorbs.
What we found:
1. The high-fiber diet changed many of the body’s metabolites compared to the processed diet. These changes could help identify diets that modulate how much energy is absorbed from the diet, in part by altering the gut microbiome.
2. Some of the changes in metabolites excreted in the stool were linked to less energy being absorbed and more growth of gut microbes—suggesting potential mechanisms by which the microbes might be using some of the energy themselves and preventing energy from being absorbed by the host.
3. Surprisingly, the high-fiber diet increased levels of a ketone body called beta-hydroxybutyrate, which usually rises during fasting or low-carb diets. This happened even though both diets had the same number of calories which were calculated to maintain participants’ starting body weight, hinting that an MBD might mimic some effects of fasting.
Why this matters:
These findings help us understand how diet and gut microbes work together to influence energy use in the body. This could lead to new ways to prevent or treat obesity by targeting the gut microbiome.
To read the full published article please click below.
Recent News
Clinical Trial Evidence on Diet and Type 1 Diabetes Outcomes
A new systematic review of clinical trials has found that no single dietary pattern consistently improves blood sugar control or weight management in youth and adults living with type 1 diabetes.
How Diet Shapes Gut Microbes and Energy Absorption
What we eat has a big impact on the bacteria living in our gut, which in turn affects how our bodies use energy—something that plays a major role in the development and treatment of obesity.
AdventHealth Neuroscience Institute Launches NIH-Funded THRIVE Trial
AdventHealth Neuroscience Institute has launched THRIVE, an NIH-funded clinical trial led by Lauren Oberlin, PhD, geriatric neuropsychologist and neuroscience researcher.
AdventHealth Tampa Enrolls First Patient in the Tectonic CAD IVL Trial
On September 19, 2025, AdventHealth Tampa successfully enrolled its first patient in the Tectonic CAD Intravascular Lithotripsy (IVL) Trial, led by Dr. Mahmaljy and his team.
MANIFEST US Study Presented as a Late-Breaking Clinical Trial at AHA
The cardiovascular team is excited to highlight the MANIFEST US study, which was presented on November 10th as a Late-Breaking Clinical Trial at the American Heart Association (AHA) Scientific...
Nourishing Your Gut: Dr. Karen Corbin on the Power of Fiber
Dr. Karen Corbin, associate investigator at the AdventHealth Translational Research Institute for Metabolism and Diabetes in Orlando, emphasizes the essential role of diet in maintaining a healthy gut...
Southeast Region – Redmond Campus: AdventHealth Recognized as Top Enroller Nationally for the CARVTOP-ICD Trial
AdventHealth Research Institute (AHRI) is proud to announce that the Southeast Region’s Redmond Campus has been recognized as the top enrolling site nationally for the CARVTOP-ICD trial.
Stiff Arteries Linked to Early Memory Decline: New Findings by Dr. Amani Norling
Amani Norling, PhD a post-doctoral fellow at the AdventHealth Neuroscience institute, has published a notable paper titled “Arterial stiffness moderates the link between NfL and cognition: The IGNITE...
First BrioVAD Implant Successfully Completed
On September 24, the Transplant team successfully implanted the first BrioVAD device at AdventHealth, a major milestone in the ongoing INNOVATE 2254936 Vidic trial.
Advancing T1D Science: New TRI Publications
Researchers at the AdventHealth Translational Research Institute continue to drive meaningful progress in Type 1 diabetes—work that is being recognized not just in Central Florida, but throughout the...
The T1D Daily Reset: Small Habits With Big Impact
As we head into 2026, many people living with Type 1 diabetes are looking for ways to reset their routines and start the year feeling more balanced and in control.
The Next Frontier: Preventing Type 1 Diabetes Before It Starts
Recent research led by AdventHealth’s Translational Research Institute and others reveals that Type 1 diabetes develops gradually and can now be detected early through blood tests, opening the door to...